Cervical cancer screening study for women with HIV in Rwanda
Part of Cancer, Immune system & allergy, Infections, Women’s health & pregnancy clinical trials.
This study tests whether using one or two screening tools (HPV test or VIA) is better at finding cervical precancer in women with HIV. It may help improve screening and treatment for cervical cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 25 and 49 years old.
- You are living with HIV.
- You have a cervix that hasn't been removed (no hysterectomy).
- You are willing to come back to the clinic in 6 months.
- You had a positive HPV test or VIA exam in the last 3 months.
- You have a type 1 transformation zone (easy to see the cervix) and are eligible for thermal ablation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different ways to treat early cervical changes caused by HPV in women living with HIV. It compares using one heating probe versus two heating probes to destroy abnormal cervical tissue, and measures which approach works better and is easier to use.
This study tests two different approaches to treating early cervical changes in women living with HIV who tested positive for HPV (a virus that can cause cervical cancer). The goal is to see which approach works better and is easier to use in South Africa.
This study tests whether using one or two probes during thermal ablation (a heat-based treatment) works better for treating early cervical changes in women living with HIV. It aims to find the best way to prevent cervical cancer.
This study aims to make cervical cancer screening easier and more accessible for women living with HIV. Researchers will test new ways to help women get screened and receive follow-up care at three clinics across the United States.
This trial tests a new way to quickly diagnose and treat cervical pre-cancer using a point-of-care device. It may help women who are HPV-positive avoid a separate treatment visit.
This study looks at how well the HPV vaccine works in women living with HIV and whether it helps make cervical cancer screening more accurate. If you are a woman with HIV between 21 and 40 years old and already part of certain other HIV studies, you may be able to join.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.